Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients

dc.contributor.buuauthorErsoy, Canan
dc.contributor.buuauthorİmamoğlu, Şazi
dc.contributor.buuauthorBudak, Ferah
dc.contributor.buuauthorTuncel, Ercan
dc.contributor.buuauthorErtürk, Erdinç
dc.contributor.buuauthorOral, Haluk Barbaros
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0003-0463-6818tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.contributor.researcheridF-4657-2014tr_TR
dc.contributor.researcheridK-7285-2012tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.contributor.scopusid6602297533tr_TR
dc.contributor.scopusid6701913697tr_TR
dc.contributor.scopusid7006929833tr_TR
dc.contributor.scopusid7005488796tr_TR
dc.contributor.scopusid7004498001tr_TR
dc.date.accessioned2022-03-14T07:59:04Z
dc.date.available2022-03-14T07:59:04Z
dc.date.issued2004-11
dc.description.abstractBackground & objectives: Tumour necrosis factor-alpha (TNF-α) has been suggested to play a key role in insulin resistance (IR) in obesity and may contribute to the development of type 2 diabetes mellitus. Recently, studies are focused on the effect of antihypertensive drugs on insulin sensitivity and cytokines. We undertook this study to evaluate the effect of amlodipine, a long-acting dihydropyridine calcium channel blocker treatment on TNF-α, homeostasis model assessment (HOMA) IR and leptin levels in obese hypertensive type 2 diabetic patients. Methods: Amlodipine 5-10 mg for 12 wk was given to type 2 diabetic patients in the amiodipine group. Pre- and post-treatment values of laboratory parameters in the amlodipine group were compared with those of normotensive nondiabetic obese controls. At baseline blood pressures (BP) and metabolic parameters were measured in all patients and repeated after 12 wk in the amlodipine group. Results: Basal waist-to-hip ratio, systolic and diastolic BPs, fasting glucose, TNF-α and HOMA-IR values of the amlodipine group were higher than the control group. No difference was detected in body mass index, fasting insulin, hemoglobin Alc and leptin values between groups. The systolic and diastolic BPs, fasting glucose, HOMA-IR and TNF-α values decreased significantly after the treatment. But, there was no correlation between percentage change in TNF-α and HOMA-IR. Interpretation & conclusion: Besides reducing BP, amlodipine seemed to improve IR and decrease TNF-α levels. In this context, these properties may provide additional benefits of antihypertensive drug regimens chosen for this population, but larger group interventions are needed.en_US
dc.identifier.citationErsoy, C. vd. (2004). “Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients”. Indian Journal of Medical Research, 120(5), 481-488.en_US
dc.identifier.endpage488tr_TR
dc.identifier.issn0971-5916
dc.identifier.issue5tr_TR
dc.identifier.pubmed15591634tr_TR
dc.identifier.scopus2-s2.0-11044234746tr_TR
dc.identifier.startpage481tr_TR
dc.identifier.urihttp://hdl.handle.net/11452/24973
dc.identifier.volume120tr_TR
dc.identifier.wos000225841600011tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.journalIndian Journal of Medical Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmunologyen_US
dc.subjectGeneral and internal medicineen_US
dc.subjectResearch and experimental medicineen_US
dc.subjectAmlodipineen_US
dc.subjectInsulin resistanceen_US
dc.subjectLeptinen_US
dc.subjectTumor necrosis factor-alphaen_US
dc.subjectSerum-levelsen_US
dc.subjectPlasmaen_US
dc.subjectSensitivityen_US
dc.subjectExpressionen_US
dc.subjectReceptoren_US
dc.subjectMellitusen_US
dc.subjectReleaseen_US
dc.subjectGlucoseen_US
dc.subjectMenen_US
dc.subject.emtreeAmlodipineen_US
dc.subject.emtreeAngiotensin 2 receptor antagonisten_US
dc.subject.emtreeBeta adrenergic receptor blocking agenten_US
dc.subject.emtreeCalcium channel blocking agenten_US
dc.subject.emtreeDipeptidyl carboxypeptidase inhibitoren_US
dc.subject.emtreeGliclazideen_US
dc.subject.emtreeInsulinen_US
dc.subject.emtreeLeptinten_US
dc.subject.emtreeLong acting drugen_US
dc.subject.emtreeMonovasen_US
dc.subject.emtreeThiazide diuretic agenten_US
dc.subject.emtreeTumor necrosis factor alphaen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAnthropometryen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBlood pressureen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCorrelation analysisen_US
dc.subject.emtreeDiastolic blood pressureen_US
dc.subject.emtreeDiet restrictionen_US
dc.subject.emtreeDose responseen_US
dc.subject.emtreeDrug mechanismen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGlucose blood levelen_US
dc.subject.emtreeHomeostasisen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHypertensionen_US
dc.subject.emtreeInsulin resistanceen_US
dc.subject.emtreeLeg edemaen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMetabolic parametersen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreeObesityen_US
dc.subject.emtreeSystolic blood pressureen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAmlodipineen_US
dc.subject.meshCalcium channel blockersen_US
dc.subject.meshDiabetes mellitus, type 2en_US
dc.subject.meshFemaleen_US
dc.subject.meshHomeostasisen_US
dc.subject.meshHumansen_US
dc.subject.meshHypertensionen_US
dc.subject.meshInsulin resistanceen_US
dc.subject.meshLeptinen_US
dc.subject.meshLipidsen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshObesityen_US
dc.subject.meshProspective studiesen_US
dc.subject.meshTumor necrosis factor-alphaen_US
dc.subject.scopusTelmisartan; Antihypertensive Agent; Hydrochlorothiazide Drug Combination Telmisartanen_US
dc.subject.wosImmunologyen_US
dc.subject.wosMedicine, general and internalen_US
dc.titleEffect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patientsen_US
dc.typeArticle
dc.wos.quartileQ4 (Immunology)en_US
dc.wos.quartileQ3en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: